clearn.png
Saturday September 25th, 2021 8:50PM

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

By The Associated Press

ATLANTA--(BUSINESS WIRE)--Jun 4, 2021--

(Nasdaq: ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today dosing of the first patient in its Phase 2b clinical trial, referred to as FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1), evaluating IMC-1 in patients with fibromyalgia.

IMC-1 is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib. This dual mechanism antiviral therapy is designed to synergistically suppress Herpes Simplex Virus-1 (“HSV-1”) activation and replication, with the end goal of reducing viral mediated disease burden.

“There is currently widespread dissatisfaction among fibromyalgia patients, healthcare providers and payers with the existing FDA approved medications for the management of fibromyalgia, most notably related to their generally poor tolerability,” commented R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Virios Therapeutics. “We are excited about the FORTRESS trial as we are testing optimized doses of IMC-1, and we will be measuring patients’ fibromyalgia related pain on a daily basis. Based on industry standard fibromyalgia patient recruitment rates, we expect to complete the trial and announce top line results in mid-2022.”

“The dosing of the first patient in this Phase 2b trial marks an important milestone for Virios, as we develop new, combination antiviral therapies to improve care standards for patients suffering from chronic diseases like fibromyalgia and irritable bowel syndrome,” said Greg Duncan, Chairman and Chief Executive Officer of Virios Therapeutics. “Virios has a unique potential to create significant value in meeting the medical need for a new, safe and effective treatment to help the large market of 10-20 million fibromyalgia patients in the U.S. and more than 200 million worldwide.”

IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. This dual mechanism antiviral therapy is designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden. IMC-1 combines two specific mechanisms of action purposely selected to inhibit HSV-1 activation and replication, thereby keeping HSV-1 in a latent (dormant) state or “down-regulating” HSV-1 from a lytic (active) state back to latency. The famciclovir component of IMC-1 inhibits viral DNA polymerase necessary for replication. The celecoxib component of IMC-1 inhibits both cyclooxegenase-2 (“COX-2”) and COX-1 enzymes, used by HSV-1 to accelerate its own replication. Virios Therapeutics holds a U.S. “Composition of Matter” Synergistic Patent (US 10,251,853) for the synergistic combination for total daily dose of famciclovir and celecoxib.

Virios Therapeutics is conducting FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1). This randomized, double-blind, multi-center, placebo-controlled Phase 2b trial is expected to enroll approximately 460 patients aged 18-65, all of whom having been diagnosed using the 2016 American College of Rheumatology diagnostic criteria for fibromyalgia. The primary endpoint for this trial will focus on reduction in pain over time, as measured daily by the Numerical Rating Scale (“NRS”) 24-Hour Recall scale via an electronic diary that the patient will use at home for sixteen weeks. In addition to assessing patient’s pain reduction, secondary endpoints will include change in fatigue, sleep disturbance, global health status, and patient function.

Virios Therapeutics (Nasdaq: ) is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by waxing and waning symptoms with no obvious etiology. Our lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.

Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial. These trial results are suggestive that IMC-1 may represent a new and novel treatment for fibromyalgia. IMC-1 has been granted fast track designation by the FDA and is currently being tested in a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (“FORTRESS”) designed to set the stage for registrational studies. The company is led by an executive team highly experienced in the successful development and commercialization of novel therapies. For more information, please visit .

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion and timing of the Phase 2b trial. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. (VIRI) undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com:

CONTACT: Dave Gentry

1-800-733-2447

+1-407-491-4498

[email protected]

or

[email protected]

KEYWORD: GEORGIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS

SOURCE: Virios Therapeutics, Inc. (VIRI)

Copyright Business Wire 2021.

PUB: 06/04/2021 07:05 AM/DISC: 06/04/2021 07:06 AM

http://www.businesswire.com/news/home/20210604005022/en

  • Associated Categories: Associated Press (AP), AP Business, AP Business - Corporate News, AP Online - Georgia News, AP Business Wire - Georgia, AP Business - Industries, AP Business - Health Care
© Copyright 2021 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Hong Kong vigil organizer arrested on Tiananmen anniversary
Police in Hong Kong have arrested an organizer of the annual candlelight vigil remembering the deadly crackdown in Beijing's Tiananmen Square and warned people not to attend the banned event as authorities mute China’s last pro-democracy voices
7:04AM ( 9 minutes ago )
Bonjour! France welcoming back (vaccinated) tourists
France is putting itself back on the menu as a destination for international tourists who have had coronavirus jabs
6:53AM ( 20 minutes ago )
EU, UK investigate Facebook over classified ad competition
European Union and British regulators have opened dual antitrust investigations into Facebook to look into whether the company distorts competition in the classified advertising market by using data it collects from rival services
6:51AM ( 22 minutes ago )
Associated Press (AP)
Global shares lower ahead of US monthly jobs report
Global shares are mostly lower ahead of the release of a U.S. monthly jobs report that is viewed as a bellwether for the recovery from the pandemic
5:44AM ( 1 hour ago )
House Dems unveil $547B infrastructure bill amid Biden talks
House Democrats are weighing in on the infrastructure negotiations between President Joe Biden and Senate Republicans
5:23AM ( 1 hour ago )
The Latest: Denmark donating unused AZ jabs to Kenya
Denmark will donate 358,700 unused vaccine doses to Kenya, saying the batch of Astra Zeneca that expires July 31 should be delivered as soon as possible
3:52AM ( 3 hours ago )
AP Business
US to swiftly boost global vaccine sharing, Biden announces
The White House says the U.S. will swiftly share millions more doses of COVID-19 vaccines with the world
9:13PM ( 10 hours ago )
The Latest: Arizona’s state-run vaccination sites to close
Arizona’s state-run COVID-19 vaccination sites, which were touted as a national model, will be shutting down later this month
6:48PM ( 12 hours ago )
Biden offers tax deal to Republicans in infrastructure talks
President Joe Biden is trying to break a logjam with Republicans on how to pay for infrastructure
6:16PM ( 12 hours ago )
AP Business - Corporate News
Swanson stays hot with 2-run HR as Braves top Nationals 5-0
Dansby Swanson continued his power surge by hitting a two-run homer in Atlanta’s four-run sixth inning and the Braves beat Patrick Corbin and the Washington Nationals 5-1
4:25PM ( 14 hours ago )
Swanson stays hot with 2-run HR as Braves top Nationals 5-1
Dansby Swanson continued his power surge by hitting a two-run homer in Atlanta’s four-run sixth inning and the Braves beat Patrick Corbin and the Washington Nationals 5-1
3:46PM ( 15 hours ago )
Knicks make surprise playoff return, need work to stay there
Everyone was about to head home for the summer when a “Let’s go Knicks
1:48PM ( 17 hours ago )
AP Online - Georgia News
AP Business Wire - Georgia
Sri Lanka braces for environmental disaster as ship sinks
Authorities in Sri Lanka are trying to head off a potential environmental disaster as a fire-damaged container ship that had been carrying chemicals was sinking off of the country’s main port
11:07PM ( 8 hours ago )
Drought saps California reservoirs as hot, dry summer looms
California's reservoirs are shrinking quickly as a drought grips the western United States
5:47PM ( 13 hours ago )
EXPLAINER: Why and when do COVID-19 vaccines expire?
How soon vaccines expire is a critical question as the Biden administration prepares to send tens of millions of unused COVID-19 doses abroad to help curb the pandemic
3:31PM ( 15 hours ago )
AP Business - Industries
The Latest: California considers new workplace mask rules
California is set to fully reopen in less than two weeks and do away with nearly all mask and social distancing requirements for vaccinated people
10:12AM ( 21 hours ago )
Slow to start, China now vaccinating at a staggering pace
After a slow start, China is now doing what virtually no other country in the world can: leveraging the power and all-encompassing reach of its one-party system and a maturing domestic vaccine industry to administer shots at a staggering pace
9:26AM ( 21 hours ago )
Africa CDC says FDA announcement on J&J issues imminent
The head of the Africa Centers for Disease Control and Prevention says he expects an update in coming days from the U.S. Food and Drug Administration on the factory contamination issues that have delayed millions of doses of the Johnson & Johnson single-shot COVID-19 vaccine around the world
8:32AM ( 22 hours ago )
AP Business - Health Care
Hong Kong vigil organizer arrested on Tiananmen anniversary
Police in Hong Kong have arrested an organizer of the annual candlelight vigil remembering the deadly crackdown in Beijing's Tiananmen Square and warned people not to attend the banned event as authorities mute China’s last pro-democracy voices
7:04AM ( 9 minutes ago )
Bonjour! France welcoming back (vaccinated) tourists
France is putting itself back on the menu as a destination for international tourists who have had coronavirus jabs
6:53AM ( 21 minutes ago )
EU, UK investigate Facebook over classified ad competition
European Union and British regulators have opened dual antitrust investigations into Facebook to look into whether the company distorts competition in the classified advertising market by using data it collects from rival services
6:51AM ( 23 minutes ago )
"Dead end": German cardinal offers to quit over church abuse
A leading German cardinal and confidante of Pope Francis has offered to resign over the church’s mishandling of clergy sexual abuse scandals and declared that the church had arrived at “a dead end.”
6:51AM ( 23 minutes ago )
Opposition: Belarusian dissident forced to confess on TV
Belarusian opposition activists say that a dissident journalist has been coerced to appear in a video on state TV in which he wept and praised the country’s authoritarian ruler
6:45AM ( 28 minutes ago )